Commercially insured PATIENTS MAY Pay $0 for their first INTRAROSA  prescription Click here

Commercially insured PATIENTS MAY Pay $0 for their first INTRAROSA prescription*

With the INTRAROSA Patient COPAY Savings Card, MOST eligible, commercially insured patients* pay:

$0 copay for the first 28-day supply
Patient Savings card
Offer valid on up to 12 uses for commercially insured patients with a valid prescription for INTRAROSA. A valid prescriber ID# is required on the prescription. Limitations apply. Click here for full Terms and Conditions.
*Eligibility requirements and patient out-of-pocket expense may vary. This offer is not valid for patients enrolled in federal or state health programs, including but not limited to Medicare, Medicaid, or TRICARE.
See More

Indication

INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact AMAG Pharmaceuticals at 1­-877-411-2510 or FDA at 1-800­-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.